DEXKETOPROFEN
Long COVID
University of CadizSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
25 Active assets in the Long COVID cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
RITONAVIR Kanecia Obie Zimmerman | Phase 2 | BB |
Paxlovid Kanecia Obie Zimmerman | Phase 2 | B |
Rapamycin Icahn School of Medicine at Mount Sinai | Phase 3 | B |
MELATONIN Duke University | Phase 2 | B |
Solriamfetol Duke University | Phase 2 | B |
View all 25 →
Same molecule, other indications
DEXKETOPROFEN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →